Tabalumab, known as atacicept, represents a novel therapeutic method for addressing immunologic diseases. This recombinant monoclonal immunoglobulin selectively inhibits B cell stimulatory factor of BAFF, a crucial https://www.targetmol.com/compound/tabalumab